337 related articles for article (PubMed ID: 25461780)
21. Molecular classification defines 4 prognostically distinct glioma groups irrespective of diagnosis and grade.
Mur P; Mollejo M; Hernández-Iglesias T; de Lope ÁR; Castresana JS; García JF; Fiaño C; Ribalta T; Rey JA; Meléndez B
J Neuropathol Exp Neurol; 2015 Mar; 74(3):241-9. PubMed ID: 25668564
[TBL] [Abstract][Full Text] [Related]
22. Molecular Genetic Profile of 300 Japanese Patients with Diffuse Gliomas Using a Glioma-tailored Gene Panel.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Fujio S; Kirishima M; Takigawa K; Hata N; Toh K; Yamamoto J; Hanaya R; Tanimoto A; Yoshimoto K
Neurol Med Chir (Tokyo); 2022 Sep; 62(9):391-399. PubMed ID: 36031351
[TBL] [Abstract][Full Text] [Related]
23. Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective?
Weller M; Reifenberger G
Curr Opin Neurol; 2020 Dec; 33(6):701-706. PubMed ID: 33177376
[TBL] [Abstract][Full Text] [Related]
24. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
25. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
[TBL] [Abstract][Full Text] [Related]
26. [OMICS and biomarkers of glial tumors].
Idbaih A
Rev Neurol (Paris); 2011 Oct; 167(10):691-8. PubMed ID: 21889780
[TBL] [Abstract][Full Text] [Related]
27. Further understanding of the pathology of glioma: implications for the clinic.
Camelo-Piragua S; Kesari S
Expert Rev Neurother; 2016 Sep; 16(9):1055-65. PubMed ID: 27228211
[TBL] [Abstract][Full Text] [Related]
28. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
29. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
30. Gliosis versus glioma?: don't grade until you know.
Rivera-Zengotita M; Yachnis AT
Adv Anat Pathol; 2012 Jul; 19(4):239-49. PubMed ID: 22692287
[TBL] [Abstract][Full Text] [Related]
31. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
Marko NF; Prayson RA; Barnett GH; Weil RJ
Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
[TBL] [Abstract][Full Text] [Related]
32. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
[TBL] [Abstract][Full Text] [Related]
33. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
34. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
35. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
36. Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines.
Kumari K; Dandapath I; Singh J; Rai HIS; Kaur K; Jha P; Malik N; Chosdol K; Mallick S; Garg A; Suri A; Sharma MC; Sarkar C; Suri V
Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):410-417. PubMed ID: 35708480
[TBL] [Abstract][Full Text] [Related]
37. Characterization of gliomas: from morphology to molecules.
Ferris SP; Hofmann JW; Solomon DA; Perry A
Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742
[TBL] [Abstract][Full Text] [Related]
38. [Histological classification of human gliomas: state of art and controversies].
Figarella-Branger D; Bouvier C
Bull Cancer; 2005 Apr; 92(4):301-9. PubMed ID: 15888386
[TBL] [Abstract][Full Text] [Related]
39. Pathology and Genetics of Gliomas.
Komori T; Muragaki Y; Chernov MF
Prog Neurol Surg; 2018; 31():1-37. PubMed ID: 29393190
[TBL] [Abstract][Full Text] [Related]
40. The Misclassification of Diffuse Gliomas: Rates and Outcomes.
Iorgulescu JB; Torre M; Harary M; Smith TR; Aizer AA; Reardon DA; Barnholtz-Sloan JS; Perry A
Clin Cancer Res; 2019 Apr; 25(8):2656-2663. PubMed ID: 30635340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
